Back to top

BMO Capital Remains a Hold on Sarepta Therapeutics (SRPT)

In a report released today, Kostas Biliouris from BMO Capital reiterated a Hold rating on Sarepta Therapeutics, with a price target of $50.00. The ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Sarepta Therapeutics, Inc. (SRPT)